



AMGEN BC QUICK FACTS

Amgen applies science and innovation to help fight serious illness and dramatically improve people's lives. Amgen believes in the transformative power of science to bring the benefits of biotechnology to more people than ever before. Amgen's Canadian research facility in Burnaby, British Columbia plays an important role in contributing to our 40-year legacy as a global leader in the identification, isolation, production and use of human proteins as therapeutic agents. The Amgen commercial team in BC works in partnership with the provincial government and other stakeholders to bring practical, cost-effective and long-term improvements to the healthcare system in British Columbia.

Today, Amgen scientists in Burnaby work on the cutting edge between the traditional disciplines of chemistry, cellular and molecular biology in an effort to discover and develop pioneering medical treatments. To support Amgen's mission of serving patients, the R&D organization aims to discover, develop, and deliver transformative medicines that address the leading causes of death and disability. Our research leverages new scientific breakthroughs for patient care, helping patients in their fight against cancer, osteoporosis, migraine, kidney disease, rheumatoid arthritis, cardiovascular disease and other serious illnesses.

AMGEN BC'S INNOVATIVE RESEARCH TECHNOLOGIES

Amgen BC's research centre is a custom-built, state-of-the-art laboratory, incorporating novel, proprietary technologies to isolate, develop and produce potential medicines. This world-class biotechnology lab enables Amgen BC to produce superior research results that translate into better therapeutic treatments.

Key to Amgen BC's leadership in biotechnology is our focus on advancing Amgen's most promising, innovative, potential new therapeutics into clinical studies, while significantly expanding the organization's understanding of the underlying causes of diseases.

The Amgen BC site operates the XenoMouse® process responsible for generating all of the company's internal discovery phase therapeutic human antibody candidates. Other advanced technologies which accelerate Amgen's ability to identify the best potential research candidates and isolate individual cells for further study have been developed at the Amgen BC site. These progressive research technologies can leverage new scientific breakthroughs for patient care faster and safer than ever before.

As a result of these technologies, early candidate molecules discovered at the Amgen BC site are then advanced by Amgen's global research teams into additional stages of characterization and development. These collaborative research efforts have led to four biologic medicines have been produced and developed into five products that are available to patients around the world: Vectibix® (panitumumab), XGEVA® (denosumab), Prolia® (denosumab), Repatha® (evolocumab), and Aimovig® (erenumab).

QUICK FACTS

Location

Burnaby, British Columbia

Staff

Burnaby Research & Development – 95
Field Staff – 15

Address/Phone

Amgen British Columbia
7990 Enterprise Street
Burnaby, British Columbia
Canada V5A 1V7
(604) 415-1800

HISTORY IN CANADA

1991 – Amgen Canada founded in Mississauga
1992 – Launch of NEUPOGEN®
2002 – Launches of Aranesp®
Amgen acquires Immunex, including Enbrel®
2004 – Launch of Neulasta® and Sensipar®
2006 – Amgen acquires Abgenix, Inc., including its Burnaby R&D group
2008 – Launch of Vectibix®
2009 – Launch of Nplate®
2010 – Launch of Prolia®
2011 – Launch of XGEVA®
2015 – Launch of Repatha®
2016 – Launch of BLINCYTO®
2016 – Launch of KYPROLIS®
2019 – Launch of MVASI®
2019 – Launch of EVENITY®
2020 – Amgen acquires Otezla®
2020 – Launch of KANJINTI®
2020 – Launch of AVSOLA®

AMGEN MEDICINES AVAILABLE IN BC

Oncology

Aranesp® (darbepoetin alfa)
Neulasta® (pegfilgrastim)
NEUPOGEN® (filgrastim)
Vectibix® (panitumumab)
XGEVA® (denosumab)
BLINCYTO® (blinatumomab)
KYPROLIS® (carfilzomib)
MVASI® (bevacizumab)
KANJINTI® (trastuzumab)

Nephrology

Aranesp® (darbepoetin alfa)
Sensipar® (cinacalcet)

Rheumatology

Enbrel® (etanercept)
Otezla® (apremilast)
AVSOLA® (infliximab)

Dermatology

Enbrel® (etanercept)
Otezla® (apremilast)
AVSOLA® (infliximab)

Bone Health

Prolia® (denosumab)
EVENITY® (romosozumab)

Hematology

Nplate® (romiplostim)

Cardiology

Repatha® (evolocumab)

ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's largest independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit amgen.ca and follow us on twitter.com/AmgenCanadaGM.

COMMITMENT TO BRITISH COLUMBIA

Amgen believes that biologic medicines have the power to change the ways we can fight disease and promote health, and the exciting scientific research being conducted in British Columbia is leading the way. Amgen's leadership in biotherapeutic research is underscored by a robust and ongoing investment in the BC life sciences industry.

Many of Amgen BC's proprietary research innovations were developed or invented in BC – a testament to the tremendous scientific talent pool that has been trained here and works in this province. We strive to attract the best and brightest minds from British Columbia's post-secondary and graduate science education programs. We also believe in investing in tomorrow's great scientists, providing training opportunities for aspiring undergraduate and graduate students to gain solid work experience through active participation in Amgen BC's MITACs scholars program. Participating BC universities may include the University of British Columbia, Simon Fraser University and the University of Victoria.

COMMUNITY INVOLVEMENT

As a leading member of the biotechnology sector, Amgen is committed to raising the value of science literacy in the community; attracting bright young minds into the field of science by helping educators to teach more effectively; and improving access to science resources for teachers, students and the community at large.

Since 2010, Amgen has supported the national non-profit group Let's Talk Science in the development and release of a series of research reports that highlight the importance of science learning for students, parents, teachers and the economy.

The *Spotlight on Science Learning* research reports can be accessed by visiting:

letstalkscience.ca/research-publications.

As a science-based company, Amgen also understands the benefits of science education, how critical STEM is to jobs and how science can power Canada's future prosperity and success for our youth. This is why Amgen is also proud to support Let's Talk Science's latest initiative, Canada 2067, an initiative to unite Canadians around a new vision for youth STEM learning with a focus on Kindergarten to Grade 12. Visit www.canada2067.ca for more information.

Further, Amgen dedicates substantial resources to strengthen and enrich communities in BC and across Canada. Amgen supports Start2Finish, and is a National Health Partner of the Advanced Coronary Treatment (ACT) Foundation of Canada.

As a leading member of the biotechnology sector, Amgen funds various members within the community including a Professorship in Sustainable Healthcare at UBC's School of Pharmacy. Amgen is also an active member of BIOTECanada and Innovative Medicines Canada.

Three Amgen Foundation global programs are now reaching teachers and students in BC: the Amgen Scholars Program through the University of Toronto, LabXchange, a science learning digital platform developed in partnership with Harvard University, and a three-year commitment as exclusive biology content funder of Khan Academy, a free, online learning website.

